

From: [Catherine St. John](#)
To: [AGO - High Cost Prescription Drugs](#)
Cc: [Kadmon Legal](#)
Subject: Pursuant to 18 V.S.A. § 4637 (Notice of Introduction of New High-Cost Prescription Drugs)
Date: Thursday, October 24, 2019 8:27:18 AM
Attachments: [image876178.PNG](#)

To Whom It May Concern:

This is to provide notice that Kadmon Pharmaceuticals, LLC has introduced a new prescription drug to market at a wholesale acquisition cost that exceeds the threshold set for a specialty drug under Medicare Part D. The information is below:

Full trade name of the drug	Clovique™ Trientine hydrochloride capsules, USP and Trientine hydrochloride capsules, USP
11-digit National Drug Code (NDC) for the drug product	66435-700-10 and 66435-0700-20

Further required information will be provided within 30 days (November 23, 2019).

Thank you,
Cate St. John



Catherine St. John | Senior Director, FDA Compliance & Regulatory Counsel
Kadmon | 450 East 29th Street | New York | NY 10016
Catherine.StJohn@kadmon.com | Main: 833.900.KDMN | Direct: 646.374.3645
www.kadmon.com | [NYSE:KDMN](#)

This transmission contains information that may be privileged, confidential and/or exempt from disclosure under applicable law. If you are not the intended recipient of this communication, please note that any use, dissemination, distribution, downloading or copying of this communication is strictly prohibited. If you have received this communication in error, please immediately notify the sender by e-mail or telephone and delete the communication and destroy all copies. Unless explicitly stated herein, nothing contained in this email or any attachment hereto is meant to be binding upon the sender or recipient. The parties can only be bound by an executed written agreement between the parties. Thank you for your cooperation.